Covid-19 vaccines: is fractional dosing a solution for supply-short Southeast Asia?
The crisis has drawn attention to a contentious remedy employed during previous infectious disease outbreaks. Fractional dosing involves administering smaller amounts of vaccines to stretch dwindling supplies. Advocates say the approach, which divides experts, warrants serious consideration as a way to rapidly expand inoculation and save lives as the coronavirus tears through unvaccinated populations.
Do you have questions about the biggest topics and trends from around the world? Get the answers with SCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought to you by our award-winning team.
In an article published in Nature Medicine earlier this month, researchers at the University of Hong Kong and University of Chicago said reduced doses had "not been given sufficient attention and consideration" as a potential solution to vaccine shortages.
The article cited evidence that reduced doses could promote a robust immune response, including a non-randomised trial of the Pfizer-BioNTech vaccine that found doses as low as one-third produced a "comparable" response to the standard dosage.
In a larger British study that inadvertently produced evidence about the effectiveness of reduced dosing, researchers reported efficacy ranging from 67 per cent to 97 per cent after administering a half-dose of the AstraZeneca vaccine followed by a full dose 12 weeks later.
"Vaccines are still going to be in limited supplies for at least another year," said Ben Cowling, an infectious disease expert at the University of Hong Kong and one of the authors of the Nature Medicine article. "Using lower doses is a strategy which could make better use of available vaccines and save lives."
Fractional dosing has been used successfully against other diseases. In 2016, the World Health Organization (WHO) approved one-fifth doses of the yellow fever vaccine as an emergency measure during major outbreaks in Angola and the Democratic Republic of Congo. The approach was repeated during Brazil's yellow fever vaccination campaign in 2018.
WHO spokesman Tarik Jasarević said there was still not "enough evidence to make policy recommendations" about reduced doses for Covid-19.
Pfizer has not studied partial doses and said in a statement that "decisions on alternative dosing regimens reside with health authorities", but emphasised that two doses afforded recipients "the maximum possible protection".
Moderna, AstraZeneca, Johnson & Johnson and Sinovac did not respond to requests for comment. Sinopharm referred inquiries to its sister company, China National Biotec Group.
Marc Lipsitch, director of the Centre for Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health, said reduced dosing had merit but more research was needed to conclusively show effectiveness against Covid-19.
"If you get more than half the immune protection from half the dose, or one-fifth of the immune protection from one-fifth of the dose ... then you can do more good by spreading it more thinly," Lipsitch said. "I think it's worth investigating."
Other experts were more sceptical. Nikolaus Osterrieder, dean of the Jockey Club College of Veterinary Medicine and Life Sciences at City University of Hong Kong, said adjusting doses could potentially cause the virus to mutate into new and more transmissible variants.
"I would really be against trying to change anything of this tested and approved protocol," Osterrieder said.
Jerome Kim, director general of the International Vaccine Institute in Seoul, said studies such as the AstraZeneca trial did not provide conclusive evidence that reduced doses would work.
"That it showed something positive was good, but it did not meet the usual standard for proof," Kim said.
"Before we jump to the conclusion that all vaccines will work equally well as fractional doses - and not knowing what this means for variants that are more transmissible and potentially more lethal - we should do some clinical trials, establish what can and cannot be used in fractional dose format."
Thira Woratanarat, an epidemiologist at Chulalongkorn University in Bangkok, said it was "arguable" whether the benefits of such an approach outweighed the risks.
"If we jump too quickly, the protective efficacy might be too low to contain the epidemic, particularly from those new variants of concern and other emerging variants of interest," Thira said, although he noted that fractional dosing has been discussed as a possibility by Thai experts.
Cowling, the infectious disease expert who argued in Nature Medicine that fractional dosing should be explored, acknowledged the need for more research but said further studies could be easily conducted.
"Some additional small trials could be done quickly to confirm the feasibility of this approach, although we already have quite a bit of data indicating that it should work very well," he said. "I'm surprised that fractionation hasn't been considered as a solution to the shortage of vaccines."
This article originally appeared on the South China Morning Post (SCMP).
Copyright (c) 2021. South China Morning Post Publishers Ltd. All rights reserved.
